Novartis AG
News and overview for Novartis AG
Novartis AG raised to outperform at Cazenove - MarketWatch
MarketWatch | 34 days 2 hours 13 minutes ago
Novartis AG raised to outperform at Cazenove
Novartis: Smaller flu-vaccine doses suffice - MarketWatch
MarketWatch | 7 days 4 hours 15 minutes ago
UBS targets annual pretax of SFR15B in medium-term
Novartis to buy 85% of Chinese vaccines producer - MarketWatch
MarketWatch | 20 days 3 hours 20 minutes ago
Barry Callebaut to buy a Spanish chocolate firm
Novartis: FDA wants more data on bronchodilator - MarketWatch
MarketWatch | 36 days 3 hours 38 minutes ago
Ampal-American 12.5% affiliate gets gas contracts
Vanda licenses schizophrenia drug to Novartis - MarketWatch
MarketWatch | 42 days 3 hours 40 minutes ago
Vanda licenses schizophrenia drug to Novartis
Novartis net flat; vaccines, charges limit growth - MarketWatch
MarketWatch | 33 days 3 hours 1 minute ago
Operating income rose 13% to $2.63 billion.
Novartis reports net income of $2.1 billion - MarketWatch
MarketWatch | 33 days 6 hours 1 minute ago
Nestle: 2% real internal growth in third quarter
Novartis to spend $1 billion on China R&D - MarketWatch
MarketWatch | 21 days 3 hours 9 minutes ago
Updates, advisories and surprises
Novartis gets rights to Paratek antibiotic - MarketWatch
MarketWatch | 47 days 4 hours 49 minutes ago
CH:NOVN
Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia [Press Release]
PRNewswire | 42 days 8 hours 39 minutes ago
...PRNewswire-FirstCall/ -- Novartis Pharma AG has entered into an agreement...risks and factors referred to in Novartis AG's current Form 20-F on file...Corporation is an affiliate of Novartis AG, which provides healthcare solutions...
Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court [Press Release]
PRNewswire | 38 days 7 hours 59 minutes ago
...risks and factors referred to in Novartis AG's current Form 20-F on file...in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG , which provides healthcare solutions...
Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients [Press Release]
PRNewswire | 35 days 1 hour 25 minutes ago
EAST HANOVER, N.J., Oct. 20 /PRNewswire/ -- Novartis announced today that Tasigna(R) (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec(R) (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna was well tolerate...
Novartis: 1st US plant for cell-based flu vaccine
CNBC | 6 minutes ago
BASEL, Switzerland - Swiss pharmaceuticals maker Novartis AG has opened the first U.S. plant to produce flu vaccines using cell cultures instead of egg-based methods, it said Tuesday.
Vanda Pharmaceuticals announces its agreement with Novartis Pharma AG
News-Medical.Net | 41 days 4 hours 21 minutes ago
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it has entered into an agreement with Novartis Pharma AG to commercialize and develop Fanapt(TM) (iloperidone), Vanda's anti-psychotic, in the U.S. and Canada. Fanapt(TM) was approved by the U.S. Food and Drug Administration on May 6, 2009 for the acute treatment of schizophrenia in adults. Fanapt((TM)) is a mixed dopamine D2 / serotonin 5HT2A receptor antagonist. The U.S. anti-psychotic market is approximately $14 billion.
Novartis: lower dose of flu vaccine sufficient
Boston Globe, The | 6 days 22 hours 20 minutes ago
BASEL, SwitzerlandPharmaceutical maker Novartis AG said Tuesday a U.S. clinical study suggests that half a dose of its swine flu vaccine may be sufficient to protect people from the virus and could allow many more to be immunized with current supplies.
Sign up for BIO SmartBrief
Company Overview
| Company: | Novartis AG |
|---|---|
| Industry: | Pharmaceuticals Manufacturers |
| Website: | http://www.novartis.com |
Although it's based in neutral Switzerland, Novartis has been aggressive in attacking illnesses on four fronts: pharmaceuticals, vaccines and diagnostics, generics, and consumer health. Its largest division, Pharmaceuticals, develops and manufactures prescription drugs to treat a wide spectrum of ailments. Vaccine and Diagnostics manufactures vaccines and blood-screening tools. Its Sandoz generics subsidiary produces generic drugs, as well as active pharmaceutical ingredients. Novartis' consumer health unit includes OTC medications such as Benefiber, Excedrin, and Theraflu, along with CIBA Vision's contact lenses and eye care products and Animal Health's companion and agricultural animal care products.
Key Numbers
| Sales in U.S. Dollars (mil.) | 42,584 (2008) |
|---|---|
| One-year % Growth in Sales | 9.3 (2008) |
| Net Income in U.S. Dollars (mil.) | 8,233 (2008) |
| One-year % Growth in Net Income | -31.2 (2008) |
| Number of Employees | 96,717 (2008) |
| One-year % Growth in Number of Employees | -1.5 (2008) |
| Fiscal Year-End | December |